Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

New Jersey IP Law Association Patent Litigation Seminar

Summary

Speakers

William M. Jay

Related Content

NLRB Concludes that Separation Agreement Provisions Prohibiting Disparagement and Requiring Confidentiality of Agreement Terms Violate Employee Rights

Cannabis Marketing Proposed Regulations in New York & Neighboring States (Bloomberg Law)

FTC Proposes a Sweeping Rule That Would Ban Nearly All US Noncompete Agreements

3 Reasons Beauty Cos. Should Consider Pursuing Patents

Recent Court Decisions Shed Light on Enforceability of Electronic Contracts in the U.S.

Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System

Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial

U.S. Government Authorizes Transactions Related to Patent Protection in Russia

Unconscious Bias Through the Lens of Pop Culture

AIPLA 2023 Spring Meeting

Reactions to Amgen v. Sanofi and the Future of Patent Law’s Enablement Requirement

Berkshire Grey Enters Into Definitive Merger Agreement with SoftBank Group

Amgen Supreme Court Arguments Aren't Just About Biology (Law360)

Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl (Pink Sheet)

Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)

Goodwin Adds 3 IP Litigators In NY (Law360)

Intellectual Property

Appellate and Supreme Court Litigation